Evidence map›Paper›PMID 39744919›Full record

ArticleClinical trials (London, England)2025

A framework for sequential monitoring of individual N-of-1 trials and combining results across a series of sequentially monitored N-of-1 trials.

Subodh Selukar, David K Prince, Susanne May

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Subodh SelukarDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-3802-488X
David K PrinceKidney Research Institute, University of Washington, Seattle, WA, USA.
Susanne MayDepartment of Biostatistics, University of Washington, Seattle, WA, USA.ORCID 0000-0002-3601-7432

Funding

Developing Data-Driven Cancer ResearchersT32CA009168 · NCI · UNIVERSITY OF WASHINGTON · PI STEPHEN M SCHWARTZ, MICHAEL Chiao-An WU · 1985 to 2026
$10.1M
STATISTICAL ISSUES IN AIDS RESEARCHR37AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI JAMES P HUGHES · 1999 to 2026
$9.8M
STATISTICAL ISSUES IN AIDS RESEARCHR01AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI HUGHES, JAMES P · 1989 to 2018
$5.3M
NCI NIH HHS T32 CA009168NIAID NIH HHS R01 AI029168NIAID NIH HHS R37 AI029168
6 · The paper itself

Abstract

backgroundN-of-1 trials compare two or more treatment options for a single participant. These trials have been used to study options for chronic conditions such as arthritis and attention deficit hyperactivity disorder. In addition, they have been suggested as a means to study interventions in rare populations that may not be tractable to include in standard clinical trials, such as treatment options for HIV-positive patients in need of organ transplant. Sequential monitoring of accruing data has been well-studied in traditional clinical trials, but these methods have not yet been implemented in N-of-1 trials. However, the option to validly stop an N-of-1 trial early could deliver faster decisions that could directly improve the patient's health.

methodsIn this work, we propose and evaluate a framework to (1) facilitate sequential monitoring in individual N-of-1 trials with a continuous outcome and (2) combine results across a series of already-completed sequentially monitored N-of-1 trials. By employing the block structure common to N-of-1 trials, we suggest that existing approaches to sequential monitoring may be employed when data from one N-of-1 trial are analyzed with a linear mixed-effects model. To combine results across a series of already-completed sequentially monitored N-of-1 trials, we propose combining the naive estimates from constituent trials in a random-effects model with inverse-variance weighting. We evaluate these proposals via simulation.

resultsWe find that type 1 error can be substantially inflated for N-of-1 trials with a small number of planned blocks but can reach the nominal rate for trials with more planned blocks or those with larger numbers of periods per block or by using a

conclusionUnder suitable design considerations, our proposed framework for sequential monitoring can support clinicians in providing important decisions earlier, on average, for patients engaged in N-of-1 trials.

Indexed as

Clinical Trials as TopicResearch DesignHumansN-of-1 trialsprecision medicinesequential monitoringsmall samples

Identifiers

PMID39744919
PMCPMC12094905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.